Paclitaxel - SuperGen
Alternative Names: PacoExtra; PaxoExtraLatest Information Update: 15 Jan 2022
At a glance
- Originator SuperGen
- Class Albumins; Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 25 May 2005 This compound is still in active development
- 23 Mar 2001 Preclinical trials in Solid tumours in USA (Inhalation)
- 31 Mar 1997 Preclinical trials in Solid tumours in USA (PO)